

**The recurrence of illness (ROI) index is a key factor in major depression that indicates increasing immune-linked neurotoxicity and vulnerability to suicidal behaviors.**

(1-10) Michael Maes\*, (3,4,11) Ketsupar Jirakran\*, (3,4) Asara Vasupanrajit, (1,2) Mengqi Niu, (1,2) Bo Zhou, (7,8,10) Drozdstoj St. Stoyanov, (3,4,5) Chavit Tunvirachaisakul.

\* Joined first authorships.

1. Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China

2. Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China

3. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

4. Ph.D. Program in Mental Health, Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

5. Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

6. Cognitive Fitness and Biopsychological Technology Research Unit, Faculty of Medicine Chulalongkorn University, Bangkok, 10330, Thailand, Bangkok, 10330, Thailand

7. Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

8. Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria

9. Kyung Hee University, 26 Kyunghedae-ro, Dongdaemun-gu, Seoul 02447, Korea

10. Research and Innovation Program for the Development of MU - PLOVDIV–(SRIPD-MUP)“, Creation of a network of research higher schools, National plan for recovery and sustainability, European Union – NextGenerationEU.

11. Center of Excellence for Maximizing Children's Developmental Potential, Department of Pediatric, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

**Corresponding author:**

Prof. Dr. Michael Maes, M.D., Ph.D., and Prof. Dr. B. Zhou, M.D., Ph.D.

Sichuan Provincial Center for Mental Health

Sichuan Provincial People’s Hospital,

School of Medicine,

University of Electronic Science and Technology of China

Chengdu 610072

China

[Michael Maes Google Scholar profile](#)

Prof. Dr. Michael Maes, M.D., Ph.D.

<https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao>

Highly cited author: 2003-2023 (ISI, Clarivate)

ScholarGPS: Worldwide #1 in molecular neuroscience; #1/4 in pathophysiology

Expert worldwide medical expertise ranking, Expertscape (December 2022), worldwide:

#1 in CFS, #1 in oxidative stress, #1 in encephalomyelitis, #1 in nitrosative stress, #1 in nitrosation,

#1 in tryptophan, #1 in aromatic amino acids, #1 in stress (physiological), #1 in neuroimmune;

#2 in bacterial translocation; #3 in inflammation, #4-5: in depression, fatigue and psychiatry.

## Abstract

Background: The first author of this paper introduced new precision nomothetic models for a major depressive episode (MDD) which incorporate quantitative scores that measure recurrence of illness (ROI).

Objective: To explore the connections between ROI and biomarkers related to an activated immune network, immune-linked neurotoxicity (INT), and a combined INT and atherogenicity index (METAMMUNE).

Methods: The study involved 67 healthy controls and 66 outpatient MDD (OMDD) participants. We utilized a Multiplex method to measure 48 cytokines, and developed INT and METAMMUNE composite scores. The measurements included triglycerides, free cholesterol, LDL and HDL-cholesterol, apolipoprotein (Apo)A1 and ApoB.

Results: A ROI index was successfully created by extracting a validated principal component, from the number of physician-rated depressive episodes, the frequency of lifetime suicidal ideation and attempts. Adverse childhood experiences accounted for 20-22% of the variance in ROI. The latter was significantly associated with INT and METAMMUNE indices, neuroticism, lifetime and current suicidal behaviors, and the phenome ( $p < 0.001$ ). Our analysis revealed that a significant portion (55.1%) of the variance in the OMDD phenome, which includes current suicidal behaviors, anxiety, and depression, can be accounted for by the regression on INT, ROI, and emotional neglect and abuse. A validated latent construct was successfully extracted from the three ROI components, INT and METAMMUNE indices.

Conclusions: ROI and associated immune-metabolic biomarkers are indicators of a shared underlying concept, specifically a ROI-neuroimmune-metabolic pathway phenotype. ROI is a

crucial indicator of the rising immune-metabolic abnormalities and heightened susceptibility to suicidal tendencies and recurrence of illness.

Key words: depression, staging, neuroimmune, immune-linked neurotoxicity, atherogenicity, biomarkers

## Introduction

In recent publications, the first author of this paper developed novel precision models for a major depressive episode (MDD) using the precision nomothetic approach [1-9]. The author utilized a theoretical framework to construct a clinical precision nomothetic model that connects clinical causal factors (such as a family history of mood and substance use disorders) and adverse childhood experiences (ACEs) with the lifetime and current phenome of depression [1,3,4,5,7]. The current phenome of MDD was understood as a factor (latent vector) derived from various scales used by psychiatrists. These scales assess the severity of depression, anxiety, chronic fatigue, self-rated severity of depression and anxiety, suicidal behaviors (SB), and self-rated health-related quality of life (HR-QoL). Therefore, the MDD phenome is conceptualized as a quantitative score based on a multitude of relevant ratings rather than a binary variable indicating the presence or absence of MDD [1,2,4,5,6,7,8,9]. As mentioned by other authors, the binary diagnosis based on DSM criteria should not be used in depression research or clinical practice. In addition, the concept of lifetime phenome was derived from neuroticism scores, the presence of lifetime anxiety disorders, and dysthymia [7]. In previous studies, the author of this paper found a strong correlation between the lifetime phenome and current phenome scores [7].

Research has found that both a positive family history and ACEs, such as physical and emotional neglect, can be predictors of the MDD phenome [3,4,5,7,8]. Additionally, it was discovered that some of these effects were mediated by the lifetime phenome of MDD [7]. Those models were built using partial least squares (PLS)-SEM analysis, which integrates factor analysis and multiple regression. At least 5,000 bootstrap samples were utilized in a multistep mediation model. After careful examination of the model fit criteria, these models were validated and found to have strong replicability [1,2,7].

Crucially, these clinical precision models also included an index of the recurrence of depressive episodes and SBs [1,3,4,5,6,7,8]. It is widely recognized that mood disorders, such as MDD, are progressive in nature. As the number of episodes increases, there is a corresponding increase in the severity of the current phenomenon and a decline in HR-QoL [3,4,7]. Various authors have proposed staging models that classify mood disorders into distinct stages [10-12]. The stages were identified based on different risk factors, including a history of mental illness in the family, patterns of early symptoms, recurrence of episodes, treatment resistance, and the level of functioning during non-episodic periods [10-12]. However, these staging models were theoretical concepts and did not incorporate predictive mathematical algorithms based on real patient data. In contrast, the primary author employed machine learning techniques, specifically factor and principal component (PC) analysis, to calculate a novel staging index known as recurrence of illness (ROI) [3,4,7]. This ROI index was developed as the first PC or factor extracted from the total number of depressive episodes experienced throughout one's lifetime, along with the frequency of lifetime suicidal thoughts (SI) and suicide attempts (SA). Significantly, the impact of ACEs on the present phenome was not only influenced by the lifetime phenome, but also by ROI. It is worth noting that a significant portion (68.5%) of the variance in the current phenome can be attributed to ROI and lifetime phenome, as indicated by Maes et al. [7]. In addition, the combination of ROI and lifetime phenome could be seen as a single factor, suggesting that both concepts are reflective manifestations of the lifetime trajectory of patients with mood disorders [7]. The presence of certain lifetime epochs, such as ACEs, recurrent acute episodes and SB (ROI), neuroticism, anxiety disorders and dysthymia, play a significant role in shaping the characteristics of the current depressive phenome.

Extensive evidence suggests that MDD is a neuroimmune disorder, where immune pathways intersect with metabolic pathways, leading to heightened immune-linked neurotoxicity (INT) [5,8,9,13,14,15,16,17]. The research team led by the primary author of the study has successfully developed a variety of precision nomothetic models to analyze the acute phase of inpatient MDD (IMDD). These models incorporate factors such as ACEs, ROI, the phenome, all linked to the intersections of neuroimmune and metabolic pathways [1,2,5,7,8,9]. The latter encompass cytokine networks, T cell activation markers and T regulatory cells, heightened atherogenicity, elevated presence of Gram-negative bacteria, irregularities in the gut microbiome, oxidative stress, antioxidant levels, and neurotrophic pathways. Within the various models, ROI emerged as a crucial element, showing a strong correlation with biomarker pathways and ultimately impacting the phenome of acute and severe IMDD. In certain cases, a single factor was derived from the three ROI components and INT networks, resulting in the formation of a ROI-INT pathway phenotype [5].

However, it is still unclear whether the connections between ACEs, ROI, the lifetime phenome, INT and metabolic pathways, and the current phenome can be established in a representative sample of outpatients with MDD (OMDD) who have varying levels of ROI and mild to severe MDD. In a recent study, the research team led by the first author examined the neuroimmune and metabolic profile of OMDD. They found that OMDD is associated with activated immune pathways, INT, and atherogenicity and their interactions [18]. One interesting discovery in patients with OMDD is that a significant portion of the variation in the severity of the current OMDD phenome (31.4%) can be reliably predicted by the impact of INT and the interaction between INT and the metabolic syndrome (MetS) [18].

Therefore, this study aims to investigate the role of ROI in OMDD. Specifically, we will explore the potential connections between ROI and both the lifetime and current phenome. Additionally, we will examine how ROI may mediate the effects of ACEs on the lifetime and current phenome. Furthermore, we will analyze the associations between ROI and INT/metabolic biomarkers of OMDD. Another question is whether the self-rated number of depressive episodes is a valid index to reflect episode number.

## Methods and Participants

### *Participants*

This study included a group of sixty-seven healthy controls and another group of 66 patients diagnosed with OMDD. OMDD patients were enrolled as outpatients at the Department of Psychiatry in King Chulalongkorn Memorial Hospital in Bangkok, Thailand. The outpatients received a diagnosis of MDD based on the criteria specified in the DSM-5 [19]. The OMDD sample we have collected accurately reflects the population of OMDD in Bangkok. This is evident from the wide range of the number of depressive episodes, which spans from 1 to 20 episodes, and the wide range of scores on the Hamilton Depression Rating Scale (HDRS) scores which varied from 7 to 33. In addition, the sample included severe and mild depression, and encompassed both non-responders and partial remitters to treatment.

The control group was recruited through verbal communication within the catchment area, specifically in Bangkok, Thailand. Individuals in good health who participated in the study included personnel, relatives of staff colleagues, and acquaintances of individuals diagnosed with OMDD. To analyze the influence of MetS on immune profiles, we selected approximately half of the controls and OMDD samples who had been diagnosed with MetS. A total of sixty-four



participants were found to have MetS, while sixty-nine did not exhibit the condition. Out of the total of sixty-seven controls, a significant number of thirty-three were found to have MetS. Similarly, among the 66 patients with OMDD, a considerable proportion of thirty-one were diagnosed with MetS.

The exclusion criteria that apply to both patients and controls are: a) neurological disorders, such as epilepsy, stroke, Parkinson's and Alzheimer's disease, multiple sclerosis, and brain tumors; b) DSM-5 axis-2 disorders, including borderline personality disorder and antisocial personality disorder; c) other axis-1 psychiatric disorders, such as autism spectrum disorders, substance use disorders, bipolar disorder, psycho-organic syndromes; schizophrenia, and schizo-affective psychosis; and d) pregnant or lactating women. Furthermore, individuals who met the criteria for the control group and had a positive familial history in first-degree relatives of suicide, depression, mania, substance use disorders, or suffered from current and/or lifetime MDD and dysthymia were excluded from the study.

Prior to their participation in the study, all participants willingly and knowingly gave their written informed consent. The research was conducted in accordance with ethical standards that are recognized globally and in Thailand, as well as in compliance with privacy laws. The inquiry received authorization (#445/63) from the Institutional Review Board of the Faculty of Medicine at Chulalongkorn University in Bangkok, Thailand.

### Clinical assessments

By utilizing a structured questionnaire and conducting interviews with both patients and controls, we collected sociodemographic and clinical data. The structured interview included a set of demographic questions, number of depressive episodes, family history of mental health

issues in first-degree family members, the applicant's medical history and use of psychotropic and medical medications. The assessment of the number of lifetime depressive episodes involved two methods: self-rating and extraction from the patient's files at the outpatient department (OPD). Most patients received treatment at our OPD from the beginning of their disorder. For a minority of patients, we recorded the number of episodes they experienced prior to visiting our outpatient department through hetero anamnesis. Therefore, an accurate approximation of the number of episodes was acquired using the OPD files. The severity of MDD was assessed by utilizing the Beck Depression Inventory II (BDI-II) and the Hamilton Rating Scale for Depression (HAM-D) [20,21]. Anxiety severity was scored using the state version of the State-Trait Anxiety Inventory (STAI) [22]. The diagnosis of MDD involved the use of the Mini International Neuropsychiatric Interview (M.I.N.I.), in a validated Thai translation [23], along with the DSM-5 criteria. In addition, the MINI was utilized for diagnosing other axis-1 conditions and for excluding other diagnosis.

A Thai translation of the ACE Questionnaire [24] was used to conduct the assessment of ACEs. The survey consists of twenty-eight items that relate to traumatic experiences in childhood and covers ten different areas. For the purposes of this research, we utilized the raw summed scores on various factors including emotional abuse, physical abuse, emotional and physical neglect, sexual abuse, domestic violence, substance abuse within the household, mental illness within the household, parental divorce, and a criminal household member. The current study also included the overall number of ACEs and the sum of three ACE subdomains, namely emotional abuse + emotional neglect + sex abuse (labeled as 3ACEs). Using the C-SSRS [25], we assessed the frequency, severity, intensity of suicidal behaviors (SB) including suicidal ideation (SI) and attempts (SA). The symptoms that were present during the month before

admission into the study were referred to as "current" (current\_SI or current\_SA), while the symptoms that occurred earlier in a person's lifetime were referred to as "lifetime" (LT\_SI and LT\_SA). In the current study we used two C-SSRS items, namely frequency of LT\_SI and LT\_SA. Furthermore, as explained previously, we extracted one factor from the current\_SI and current\_SA items (labeled current\_SB). To assess major personality traits, we used the Thai translation of the Big Five Inventory (BFI) [26,27]. In this study, the researchers utilized the neuroticism scores, which were identified as a significant factor in the LT phenome of MDD [28].

The recurrence of illness (ROI) index was computed by utilizing the number of depressive episodes, LT\_SI, and LT\_SA items to derive the first principal component. The associations with other biomarker and clinical data were investigated in the total study sample and in the restricted group of MDD patients. In addition, we also investigated an adjusted ROI index (labeled adjusted ROI) which used the number of episodes – 1 (thus considering the first episodes as zero episodes). The latter index was used to minimize the effect of the diagnosis (MDD versus HC). Moreover, the results were also checked after transforming the ROI scores in fractional rank and log<sub>10</sub> transformation. The severity of the LT phenome was conceptualized as the first PC extracted from neuroticism, number of LT anxiety disorders, and dysthymia [7]. The severity of the current OMDD phenome (labeled as current\_phenome) was determined as the first principal component derived from the HAMD, STAI, BDI and current\_SB scores [7]. As mentioned in the Statistics section, each of these PCs met the prespecified quality criteria with great rigor.

The diagnostic criteria outlined in the DSM-5 were used to diagnose tobacco use disorder (TUD). The BMI was determined by dividing the weight (in kilograms) by the square of the height (in meters). MetS was defined based on the criteria outlined in the 2009 Joint Scientific

Statement of the American Heart Association/National Heart, Lung, and Blood Institute [29]. It requires the presence of three or more of the following components: a) a low HDL-cholesterol levels, b) a high triglyceride level, c) an increased waist circumference or BMI, d) elevated fasting glucose levels or diabetes diagnosis, and e) high blood pressure.

Analyses.

During the designated time frame of 8:00 and 9:00 a.m., we collected a volume of twenty-five milliliters of fasting venous blood from every participant in the study. This was done by utilizing a serum tube and a disposable pipette. Next, the blood was spun at a rapid speed of 35,000 revolutions per minute to separate its components. The resulting serum was carefully collected and stored in Eppendorf tubes. These containers were then kept at a freezing temperature of -80 degrees Celsius until they were thawed for the biomarker assays. A total of forty-eight cytokines, chemokines, and growth factors were examined to determine their fluorescence intensities (FI) using the Bio-Plex Multiplex Immunoassay reagent provided by Bio-Rad Laboratories Inc., located in Hercules, USA [30]. As explained in the latter study, we successfully identified the first principal component derived from 10 differentially expressed and upregulated cytokines/chemokines/growth factors (labeled immune network index). Most importantly, this PC showed high loadings ( $>0.60$ ) on 10 cytokines/chemokines/growth factors, and protein-protein interaction (PPI) analysis showed that these 10 immune compounds formed a tight PPI network [30]. The 10 upregulated components are: interleukin-4 (IL-4), IL-9, IL-17, CCL4, CCL5, CXCL12, PDGF (platelet-derived growth factor), tumor necrosis factor (TNF)- $\alpha$ , TNF- $\beta$ , and IL-1 receptor antagonist. In addition, analysis of annotations revealed that this PPI network was enriched in immune functions, such as “defense response”, “inflammatory

response”, “cytokine-mediated signaling pathway”, and “chemotaxis” [30]. We also identified 5 downregulated genes, namely IL-10, CCL3, colony-stimulating factor (CSF)1, vascular endothelial growth factor (VEGF), and NGF (neuronal growth factor) and extracted one validated PC (labeled: PCdown) [30]. Further analysis revealed that the PPI network of these downregulated genes was enriched in functions such as “positive regulation of neurogenesis”, “regulation of neuron death”, “negative regulation of neural death”, and “regulation of microglial cell migration”. Consequently, we have constructed a new composite which reflects immune-inflammatory pathways versus lowered regulation of key neuroprotective functions as z immune network index – z PCdown (labeled as immune-linked neurotoxicity index or INT).

As explained previously [7,18], the concentrations of total cholesterol, HDL-cholesterol, triglycerides, and direct LDL-cholesterol were determined using the Alinity C (Abbott Laboratories, USA; Otawara-Shi, Tochigi-Ken, Japan). The ApoA1 and ApoB concentrations were determined using immunoturbidimetric assays with the Roche Cobas 6000 and c501 modules from Roche (Rotkreuz, Switzerland). By utilizing the Free Cholesterol Colorimetric Assay reagent (Elabscience, cat number: E-BC-K004-M) we measured free cholesterol. Consequently, we constructed a new atherogenic index as  $z \text{ ApoB} + z \text{ triglycerides} + z \text{ free cholesterol} + z \text{ LDL-cholesterol} - z \text{ HDL-cholesterol} - z (1 - \text{free cholesterol} / \text{total cholesterol}) - z \text{ ApoA1}$  [18]. Finally, a new biomarker index that integrated increased INT and atherogenicity was constructed as  $z \text{ INT index} + z \text{ atherogenicity index}$  (labeled as METAMMUNE). As such, in the current study we used three biomarker indices: immune network index, INT, and METAMMUNE. Since previously [18] we observed significant interactions between MetS and immune network index we also included this interaction term and the ROI x MetS interaction.

## Statistical analysis

To achieve feature reduction, PCA was conducted to consolidate the variables into a singular PC score. For determining factorability, we employed the Bartlett's sphericity test and the Kaiser-Meyer-Olkin test for sample adequacy. To create clinical PC models that accurately represent an underlying concept, specific criteria were used: the first PC was deemed acceptable if it explained more than 50% of the variance, all loadings on the initial PC were above 0.66, and Cronbach's alpha exceeded 0.7.

An analysis of variance (ANOVA) was used to examine scale variables across different diagnostic groups. For the purpose of comparing nominal variables across different categories, we employed either the chi-square test or Fisher's Exact Probability Test. To establish the connections between two sets of scale variables, we utilized either Pearson's product moment or Spearman's rank order correlation coefficients. A thorough analysis was conducted to examine the connections between various explanatory variables (ACEs, biomarkers) and dependent variables (clinical phenome data) through the utilization of multiple regression analysis. We employed a manual approach and further utilized a forward stepwise automatic regression method to determine the most accurate predictors for the model. We set inclusion and exclusion p-values at 0.05 and 0.06, respectively. The final regression models included standardized coefficients, t-statistics, and exact p-values for each significant explanatory variable. Additionally, the total variance was represented by effect size measures such as partial eta squared ( $R^2$ ), or and F statistics (along with p values) were also considered. The presence of heteroskedasticity was assessed using the White and modified Breusch-Pagan test. The analysis of collinearity and multicollinearity involved the examination of various factors such as tolerance

(with a cut-off value of less than 0.25), variance inflation factor (with a cut-off value of greater than 4), condition index, and variance proportions from the collinearity diagnostics table.

The data distributions were subjected, where needed, to various normalization processes, such as rank-based, logarithmic, square-root, and inverse normal transformations. Furthermore, the data underwent z-score transformation to enhance their interpretability and generate z-unit-weighted composite scores that accurately depict distinct immune profiles. In each of the investigations mentioned, a two-tailed design was used to determine statistical significance at an  $\alpha$  value of 0.05. The software used was IBM Windows SPSS version 29.

The estimated a priori sample size was calculated using G\*Power 3.1.9.4 and applied to the primary analysis, which involved conducting a multiple regression analysis of ROI on ACEs and biomarkers. Based on an effect size  $f$  value of 0.25 (which accounts for approximately 10% of the variance), along with a maximum of 5 explanatory variables, an alpha value of 0.05, and a power of 0.8, it was determined that a minimum sample size of 122 was necessary. It should be added that the post-hoc estimated power for the same analysis was 0.999.

## Results

### *Sociodemographic, clinical and biomarker data in patients and controls*

**Table 1** shows the sociodemographic and clinical data of the patients and controls in the current study. There were no significant differences in age, sex ratio, education years, marital status, current smoking, BMI, MetS ratio, mild COVID-19 infection, between the two study groups. The unemployment rate was significantly higher in OMDD patients than in controls. All clinical scores were significantly higher in patients than in controls. This table also displays the

mean values of the three biomarkers in patients versus controls. The three biomarker scores were significantly increased in patients as compared with controls.

#### *Number of episodes and construction of the ROI scores*

There were significant associations between the OPD-rated and self-rated number of episodes, using Pearson's ( $r=0.804$ ,  $p<0.001$ ,  $n=133$ ) and Spearman's rank order ( $r=0.981$ ,  $p<0.001$ ) correlation coefficients. In the restricted group of OMDD patients, there were significant associations between the OPD-rated and self-rated number of episodes using Pearson's ( $r=0.690$ ,  $p<0.001$ ,  $n=66$ ) and Spearman's rank order ( $r=0.862$ ,  $p<0.001$ ) correlation coefficients. Using the Wilcoxon Signed Rank test, the median of differences between OPD-rated and self-rated episode number was significantly different ( $p<0.001$ ). Table 1 shows that the number of depressions was significantly higher when self-rated as compared with the clinician OPD ratings.

**Table 2** shows how we constructed the first ROI index based on PC analysis performed on number of OPD-rated episodes (in log<sub>10</sub> transformation), LT\_SI and LT-SA. The first PC explained 75.02% of the total variance and Cronbach's alpha was 0.819. All three variables loaded highly on this PC ( $>0.801$ ). We also performed a PCA on the adjusted OPD-rated number of episodes, and both LT\_SB data and found that the first PC explained 74.61% of the variance, all loadings were  $> 0.795$  and Cronbach's alpha was more than adequate at 0.815 (labeled adjusted ROI). As such, two reliable PCs reflecting ROI could be constructed.

#### *ACEs predict ROI.*



**Table 3** shows the results of multiple regression analyses with the ROI scores as dependent variable and ACEs as explanatory variables. We found that (regression #1) 19.1% of the variance in the OPD-rated number of episodes was explained by total sum of ACEs, and that 22.7% of the variance in ROI (regression #2) was explained by total ACE score and male sex. The same variables explained 22.6% of the variance in the adjusted ROI score ( $F=19.02$ ,  $df=2/1030$ ,  $p<0.001$ ; total AEC score:  $t=5.82$ ,  $p<0.001$ ; male sex:  $t=2.21$ ,  $p=0.029$ ). To define the most important types of ACEs, the total sum ACE score was deleted from the analysis, indicating that divorce, physical and sexual abuse were the most prominent ACE subtypes (regression #3). **Figure 1** shows the partial regression of ROI on the 3ACEs score (after adjusting for age, sex, education). Consequently, we have entered the three biomarker scores in the analysis and detected that 30.5% of the variance in ROI was explained (regression #4) by divorce, emotional abuse and neglect and the METAMMUNE score.

#### *Correlations between ROI and clinical data*

**Table 4** shows the correlations between the ROI score and all clinical data in the total study group and in the restricted study sample of OMDD patients. In the former study sample, ROI was significantly correlated with all clinical data including ACE scores, severity of the LT and current phenome and LT and current SBs and the biomarker data as well. **Figures 2 and 3** show the partial regressions of the METAMUNNE and INT indices on ROI scores (after adjusting for sex, age, BMI, and ACEs). In subjects with OMDD, ROI was significantly correlated with the ACE scores, neuroticism, LT and current phenome, SB, and the METAMMUNE index.

**Table 5** shows the results of multiple regression analyses with the clinical outcome data as dependent variables and ACEs scores and biomarkers as explanatory variables. Regression #1 shows that 47.4% of the variance in the LT\_phenome was associated with ROI and emotional abuse. **Figure 4** shows the partial regression of the lifetime phenome score on ROI (after controlling for sex, education, BMI, and MetS). Regression #2 shows that 55.1% of the variance in the current\_phenome was explained by ROI, INT index, emotional neglect and abuse. **Figure 5** shows the partial regression of the current phenome on ROI after adjusting for sex, age, education, body mass index, and MetS). In the restricted OMDD group (regression #3), we found that 40.9% of the variance in the current\_phenome was explained by ACEs (sexual abuse and emotional neglect) and the interaction term ROI x MetS.

The associations between the ROI components and the INT and METAMMUNE indices were so important that one validated PC could be extracted from the 5 variables. The construction of this PC is shown in Table 2 (labeled ROI-pathway phenotype). Cronbach's alpha was 0.810.

## Discussion

### *Computation of ROI*

A first notable finding of this study is that individuals' self-rated number of episodes aligns reasonably well with the actual number of episodes determined by physicians. This is evident from the significant Spearman correlation coefficient between the self-rated and physician-rated number of episodes. However, the number of episodes that patients reported was higher than what physicians rated, indicating that patients may have somewhat exaggerated their own number of episodes. However, the disparities are reduced once the self-rated data is

transformed using transformations (e.g. rank order). Therefore, the self-rated number of episodes are valuable for calculating the ROI index albeit they may have to be processed in transformations.

In the current study focusing on Thai OMDD, a ROI index was successfully developed using the number of episodes (in log or rank transformations) and the frequency of lifetime suicidal ideation and suicidal behaviors. In previous studies, similar ROI indices were computed for OMDD patients in Brazil and Thailand [3,4,5,6,7,9]. It is crucial to understand that these factors must demonstrate high quality fit standards, such as having satisfactory AVE, Cronbach's  $\alpha$  or composite reliability values, and displaying appropriate loadings ( $>0.66$ ) for all variables on the latent vectors.

Furthermore, it is worth noting that researchers have also developed a comparable ROI index for individuals diagnosed with bipolar disorder (BD) [3,4,31]. From the number of depressive episodes, (hypo)manic episodes, and frequency of suicidal ideation and self-harm, researchers have identified a consistent factor in BP patients [3,4,31]. These results show that the recurrence of depressive, (hypo)manic episodes, and suicidal behaviors are manifestations of the same underlying concept, namely ROI.

It is widely known that mood disorders, such as MDD and BD, are recurrent disorders with a higher risk for suicidal behaviors, including suicide attempts [32-34]. Nevertheless, course trajectory specifiers have been largely overlooked in the diagnostic systems, including those of the DSM and ICD. Disorders in the DSM/ICD are categorized according to their symptoms and symptom clusters, along with few course specifiers like bipolarity and rapid cycling. A recent project proposed the development of a clinical course-graphing scale for DSM-5 disorders, which is an interesting concept to consider. They introduced the Timeline Course Graphing Scale

for the DSM-5 Mood Disorders (TCGS) [35], which is a specific tool used for tracking the progression of mood disorders. This approach utilizes a meticulously organized technique for mapping out the course of mood disorders, allowing researchers to make well-informed evaluations regarding the timing of onset (early or late) and the severity of the illness (chronicity, subthreshold syndrome, etc.). Unfortunately, the main goal of the TCGS is to distinguish between MDD and the new DSM-5 classification called Persistent Depression, rather than measuring ROI scores. A different approach to examining the alternating symptoms in mood disorders is the NIMH Life Chart Method (LCM-p) [36]. Earlier studies conducted by Kapczinski et al. [11], Berk et al. [10], and Ferensztajn et al. [12] put forth staging indices that were developed using a theoretical framework. However, all these staging indices lacked validated mathematical ROI algorithms as the ROI constructed in the current study.

#### *Connections between ACEs and ROI*

Through this study, it has been determined that the cumulative effect of ACEs such as parental divorce, physical abuse, and sexual abuse, have a significant impact on the variance in ROI, accounting for approximately 20-22.7% of the variance. In previous studies, it has been found that ACEs highly predicted ROI in individuals with OMDD and bipolar disorder (BD) in Brazil, as well as in patients with severe OMDD in Thailand [1,3,4,5,7,18]. In addition, a recent study revealed a significant correlation between a risk/resilience ratio and the ROI score. The researchers computed this risk/resilience ratio by dividing the ACE sum score by a composite of antioxidant defenses, namely an antioxidant gene (Q192R paraoxonase 1 gene variant and its corresponding enzyme PON1). Remarkably, this ratio accounted for a substantial 20.4% of the variance in the ROI score [4].

In the present study, it was observed that there was a strong and significant correlation between ROI and the lifetime phenome, which is a composite of neuroticism, dysthymia, and lifetime anxiety disorders. Additionally, ROI was found to be significantly associated with the current phenome. In previous studies, it was reported that the combined impacts of different ACE factors, which influence outcome variables like the current phenome and current SBs, are partially mediated by ROI [1,3,4,5] and that ROI, in turn, is correlated with the presence of functional disabilities, neurocognitive deficits, and progressive deterioration [1,3]. These results extend previous studies which have shown a correlation between ACEs and a higher frequency of recurring episodes [37,38,39], elevated risk for subsequent suicidal behaviors [40,41], more severe depression [42-46], and a decline in HR-QoL [47-50].

#### *Associations between ROI and INT biomarkers*

The major finding of the current study is the strong correlation between ROI and biomarkers of an activated immune network, INT, and the interaction between INT and metabolic disorders including atherogenicity. Previous studies have demonstrated a correlation between a higher frequency of episodes and relapses with pro-inflammatory cytokines, C-reactive protein, neopterin, and oxidative stress damage, as indicated by malondialdehyde [51,52,53]. Earlier research has demonstrated a correlation between ROI and a higher body mass index (BMI), the metabolic syndrome (MetS), and elevated insulin resistance [54,55]. More recent studies have shown that ROI is associated with cytokine networks, T cell activation and lowered T regulatory cells, oxidative damage, lowered antioxidant and neurotrophic factors, and a specific gut dysbiosis endotype [5,6,7,8,56,57,58].

In addition, the study successfully extracted a reliable PC from the three ROI components along with the INT and METAMMUNE indices. This suggests that both ROI and these biomarkers are expressions of the same latent concept, which is a ROI-neuroimmune-metabolic pathway phenotype. In a previous discussion, we highlighted the potential of the precision nomothetic approach in creating new pathway phenotypes [1]. This involves effectively combining phenotypic features with biomarker pathways in replicable and validated latent vectors [1]. In previous studies, pathway phenotypes in MDD have been identified, such as the construction of a ROI-neuroimmune-growth factor pathway phenotype [5]. In a separate study, the first author's laboratory successfully developed a pathway phenotype by utilizing ROI and paraoxonase 1 (PON1) gene variants along with PON1 enzymatic activity which ultimately increased neuro-oxidative neurotoxicity [1,3]. Thus, the combination of ROI and immune or oxidative neurotoxic pathways plays a crucial role in shaping the phenome of MDD. Importantly, there is evidence that episodes of MDD and (hypo)mania can have negative impacts on neuronal functions in the brain as demonstrated by changes in neurocognitive functions, overall psychological disabilities, and brain imaging techniques [59]. Therefore, when ACEs are combined with reduced protective factors (including genetically determined antioxidant levels), it can lead to a cycle where the impact on the brain's reward system and toxic pathways becomes more pronounced, ultimately increasing the risk and severity of the current phenome.

In the context of temporal lobe epilepsy (TLE), an intriguing observation emerges. A pathway phenotype has been constructed by considering various symptoms of general psychopathology, such as depression and anxiety, along with factors like oxidative stress toxicity and reduced antioxidant levels [60]. In addition, the researchers found that the frequency of episodes in TLE was linked to higher levels of neurotoxicity, as indicated by increased neuro-

oxidative stress and reduced antioxidant defenses, including PON1 activity [60]. These recent findings indicate a progressive rise in "epileptogenic kindling" caused by the combined impact of neurotoxicity. As such, the "kindling" of episode frequency in epilepsy and ROI in MDD are both linked to neurotoxicity processes.

### *Clinical relevance of ROI*

From the information provided, it can be inferred that ROI plays a significant role in mood disorders. Increasing ROI suggests a repeated activation of the immune system and oxidative stress and the resulting neurotoxicity leading to higher susceptibility to a relapsing-remitting pattern, more severe lifetime symptoms such as neuroticism, dysthymia, and anxiety disorders, as well as increased severity of new episodes and suicidal behaviors. Moreover, ROI plays a crucial role in mediating the effects of gene variants including the PON1 Q192R gene and ACEs on the phenome [3] and, therefore, determines the lifelong trajectory of individuals with MDD, starting from genetic variants and ACEs, leading to the development of behavioral deficits.

From a clinical perspective, it is important to consider the ROI index when assessing the patient's condition and, therefore, ROI should be incorporated into the clinical diagnosis. In a recent study, a novel clinimetrics method called Research and Diagnostic Algorithmic Rules (RADAR) was developed which encompasses quantitative scores of all relevant features of MDD, including ACEs, ROI, and phenome features [6]. Moreover, these quantitative RADAR scores may be presented graphically in RADAR or spider graphs [6,31]. These graphs provide a visual representation of all patient's characteristics, including ROI, thus shaping a unique fingerprint. By simply looking at the spider graphs, one can quickly estimate the key traits and

severity of the illness. Therefore, it is important for biomarker research in mood disorders to utilize these RADAR scores to analyze associations between biomarker pan-omics data and the relevant clinical scores, including ROI, lifetime and current suicidal behaviors and phenome characteristics. Hence, it is more beneficial to employ our quantitative scores of ROI and the phenome in statistical analyses or machine learning techniques rather than depending on incorrect binary DSM/ICD diagnoses [1,6,31].

#### Limitations.

Future research should investigate the effects of ROI on brain imaging data including metabolic and hemodynamic changes as measured with functional near infrared spectroscopy, the brain connectome as measured with functional magnetic resonance imaging [61,62], and neuronal damage markers of depression [63]. Since the studies of the first author were performed in Thai and Brazil patients, the results deserve replication in other countries and ethnicities. Lastly, more research is needed on the impact of ROI in MDD versus BD patients [31].

#### Conclusions

This study constructed a ROI index based on number of physician-rated depressive episodes, frequency of suicidal ideation and attempts by extracting one validated principal component. Around 20-22% of the variance in this ROI score was explained by ACEs. ROI was significantly associated with the INT and METAMMUNE indices, neuroticism, lifetime and current suicidal behaviors, and the severity of the OMDD phenome. We found that 55.1% of the variance in the phenome of OMDD is explained by INT, ROI, and ACEs. We were able to extract a validated latent construct from the three ROI components, INT and METAMMUNE



indices, indicating that ROI and the immune-metabolic pathways are expressions of the same latent concept, namely a ROI-neuroimmune-metabolic pathway phenotype.

All in all, ROI is a key factor indicating increasing immune-metabolic aberrations and vulnerability to develop new episodes and suicidal behaviors. Future research should always ROI-define the study samples and examine the associations between ROI and biomarkers, and the mediating effects of ROI on the depression phenome. Consequently, ROI is a new drug target to treat depression and prevent further episodes and suicidal behaviors. Consequently, novel treatments should target the immune-linked neurotoxicity pathways and atherogenicity delineated in OMDD.

### **Ethics approval and consent to participate.**

The research project (#445/63) was approved by the Institutional Review Board of Chulalongkorn University's institutional ethics board. All patients and controls gave written informed consent prior to participation in the study.

### **Author's contributions**

Conceptualization and study design: MM and JK; first draft writing: MM; statistical analysis: MM; editing: all authors; recruitment of patients: JK. All authors approved the last version of the manuscript.

### **Funding**

This work was supported by the Ratchadapiseksompotch Fund, Graduate Affairs, Faculty of Medicine, Chulalongkorn University (Grant number GA64/21), a grant from CU Graduate School Thesis Grant, and Chulalongkorn University Graduate Scholarship to Commemorate the 72nd Anniversary of His Majesty

King Bhumibol Adulyadej to KJ; the Thailand Science research, and Innovation Fund Chulalongkorn University (HEA663000016), and a Sompoch Endowment Fund (Faculty of Medicine) MDCU (RA66/016) to MM, and Grant No BG-RRP-2.004-0007-C01, Strategic Research and Innovation Program for the Development of MU - PLOVDIV - (SRIPD-MUP), Creation of a network of research higher schools, National plan for recovery and sustainability, European Union - NextGenerationEU.

### **Conflict of interest**

The authors have no commercial or other competing interests concerning the submitted paper.

### **Data Availability Statement.**

The dataset generated during and/or analyzed during the current study will be available from the corresponding author upon reasonable request and once the dataset has been fully exploited by the authors.

## References.

1. Maes M. Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self. *J Pers Med*. 2022 Mar 5;12(3):403. doi: 10.3390/jpm12030403. PMID: 35330403; PMCID: PMC8955533.
2. Stoyanov D, Maes MH. How to construct neuroscience-informed psychiatric classification? Towards nomothetic networks psychiatry. *World J Psychiatry*. 2021 Jan 19;11(1):1-12. doi: 10.5498/wjp.v11.i1.1. PMID: 33511042; PMCID: PMC7805251.
3. Maes M, Moraes JB, Congio A, Bonifacio KL, Barbosa DS, Vargas HO, Michelin AP, Carvalho AF, Nunes SOV. Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress. *Mol Neurobiol*. 2019 Sep;56(9):6626-6644. doi: 10.1007/s12035-019-1552-z. Epub 2019 Mar 25. PMID: 30911933.
4. Maes M, Moraes JB, Bonifacio KL, Barbosa DS, Vargas HO, Michelin AP, Nunes SOV. Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach. *Metab Brain Dis*. 2021 Mar;36(3):509-521. doi: 10.1007/s11011-020-00656-6. Epub 2021 Jan 7. PMID: 33411213.
5. Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Debnath M, Basta-Kaim A, Kubera M, Almulla AF, Sughondhabiroom A. Adverse Childhood Experiences Predict the

Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles. *Cells*. 2022 May 7;11(9):1564. doi: 10.3390/cells11091564. PMID: 35563878; PMCID: PMC9105661.

6. Maes M, Moraes JB, Congio A, Vargas H, Nunes S. Research and Diagnostic Algorithmic Rules (RADAR) for mood disorders, recurrence of illness, suicidal behaviours, and the patient's lifetime trajectory. *Acta Neuropsychiatr*. 2023 Apr;35(2):104-117. doi: 10.1017/neu.2022.31. Epub 2022 Nov 16. PMID: 36380512.

7. Maes M, Zhou B, Jirakran K, Vasupanrajit A, Boonchaya-Anant P, Tunvirachaisakul C, Tang X, Li J, Almulla AF. Towards a major methodological shift in depression research by assessing continuous scores of recurrence of illness, lifetime and current suicidal behaviors and phenome features. *J Affect Disord*. 2024 Apr 1;350:728-740. doi: 10.1016/j.jad.2024.01.150. Epub 2024 Jan 20. PMID: 38246281.

8. Maes M, Almulla AF. Research and Diagnostic Algorithmic Rules (RADAR) and RADAR Plots for the First Episode of Major Depressive Disorder: Effects of Childhood and Recent Adverse Experiences on Suicidal Behaviors, Neurocognition and Phenome Features. *Brain Sci*. 2023 Apr 24;13(5):714. doi: 10.3390/brainsci13050714. PMID: 37239186; PMCID: PMC10216708.

9. Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Gałeczki P, Sughondhabirom A, Basta-Kaim A. The Immune Profile of Major Dysmood Disorder: Proof of Concept and

Mechanism Using the Precision Nomothetic Psychiatry Approach. *Cells*. 2022 Mar 31;11(7):1183. doi: 10.3390/cells11071183. PMID: 35406747; PMCID: PMC8997660.

10. Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, Conus P, Bechdorf A, Moylan S, Malhi GS (2014) Stage managing bipolar disorder. *Bipolar Disord* 16(5):471-417.

11. Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vázquez GH, Vieta E, Berk M (2009) The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 33(8):1366-1371.

12. Ferensztajn E, Remlinger-Molenda A, Rybakowski J (2014) Staging of unipolar affective illness. *Psychiatr Pol* 48(6):1127-1141.

13. Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. *Neuropsychobiology*. 1990-1991;24(3):115-20. doi: 10.1159/000119472. PMID: 2135065.

14. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. *Psychol Med*. 1992 Feb;22(1):45-53. doi: 10.1017/s0033291700032712. PMID: 1574566.

15. Maes M, Yirmiya R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. *Metab Brain Dis.* 2009 Mar;24(1):27-53. doi: 10.1007/s11011-008-9118-1. Epub 2008 Dec 16. PMID: 19085093.

16. Maes M, Carvalho AF. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. *Mol Neurobiol.* 2018 Dec;55(12):8885-8903. doi: 10.1007/s12035-018-1016-x. Epub 2018 Apr 2. PMID: 29611101.

17. Almulla AF, Abbas Abo Algon A, Tunvirachaisakul C, Al-Hakeim HK, Maes M. T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors. *J Adv Res.* 2023 Nov 13:S2090-1232(23)00349-1. doi: 10.1016/j.jare.2023.11.012. Epub ahead of print. PMID: 37967811.

18. Maes M, Jirakran K, Vasupanrajit A, Zhou B, Tunvirachaisakul C, Stoyanov D, Almulla AF. Are abnormalities in lipid metabolism, together with adverse childhood experiences, the silent causes of immune-linked neurotoxicity in major depression?

medRxiv 2024.02.20.24302841; doi: <https://doi.org/10.1101/2024.02.20.24302841>

19. American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed, Arlington, VA, US, American Psychiatric Publishing, Inc.

20. Beck, A. T., Steer, R. A., Brown, G. K. 1996. BDI-II, Beck Depression Inventory: Manual, Psychological Corporation.
21. Hamilton, M. 1960. A rating scale for depression. *J Neurol Neurosurg Psychiatry*, 23, 56-62.
22. Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970). *Manual for the State-Trait Anxiety Inventory*. Palo Alto, CA: Consulting Psychologists Press.
23. Kittirattanapaiboon, P., Khamwongpin, M., 2005. The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.)-Thai version. *Journal of Mental Health of Thailand* 13, 126-136.
24. Rungmueanporn L, Buathong N, Chandarasiri P, Wittayasai WJCMB. Development of the Adverse Childhood Experiences (ACE) Questionnaire Thai version. 2019;1(3):251-260.
25. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry*. 2011;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704. PMID: 22193671; PMCID: PMC3893686.
26. John, O. P., Srivastava, S. *The Big Five Trait taxonomy: History, measurement, and theoretical perspectives*. 1999.

27. Luangsurong, N. 2016. Relationship between big 5 personality traits and climate friendly product purchase intention. Thammasat University
28. Vasupanrajit A, Maes M, Jirakran K, Tunvirachaisakul C. Brooding and neuroticism are strongly interrelated manifestations of the phenome of depression. *Front Psychiatry*. 2023 Dec 22;14:1249839. doi: 10.3389/fpsy.2023.1249839. PMID: 38188051; PMCID: PMC10766685.
29. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5. PMID: 19805654.
30. Maes M, Jirakran K, Vasupanrajit A, Zhou B, Tunvirachaisakul C, Almulla AF. Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are all associated with neurotoxic immune networks and their intricate interactions with metabolic syndrome. medRxiv 2024.01.20.24301553; doi: <https://doi.org/10.1101/2024.01.20.24301553>



31. Maes M. Toward the Use of Research and Diagnostic Algorithmic Rules to Assess the Recurrence of Illness and Major Dysthymic Disorder Features: The Diagnosis “Bipolar Disorder” Is Useless. In: Stoyanov, D., Draganski, B., Brambilla, P., Lamm, C. (eds) Computational Neuroscience. Neuromethods, 2023;199:31-52 (Humana, New York, NY. [https://doi.org/10.1007/978-1-0716-3230-7\\_3](https://doi.org/10.1007/978-1-0716-3230-7_3)).
32. Bolton JM, Gunnell D, Turecki G. Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
33. Miret M, Ayuso-Mateos JL, Sanchez-Moreno J, Vieta E. Depressive disorders and suicide: Epidemiology, risk factors, and burden. Neurosci Biobehav Rev 2013;37(10 Pt 1):2372-2374.
34. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010;12(1):1-9.
35. McCullough JP Jr, Clark SW, Klein DN, First MB. Introducing a Clinical Course-Graphing Scale for DSM-5 Mood Disorders. Am J Psychother 2016;70(4):383-392. doi: 10.1176/appi.psychotherapy.2016.70.4.383. PMID: 28068500.
36. Denicoff KD, Ali SO, Sollinger AB, Smith-Jackson EE, Leverich GS, Post RM. Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings

in clinical trials of bipolar disorder. *Depress Anxiety* 2002;**15**(1):1-9. doi: 10.1002/da.1078. PMID: 11816046.

37. Etain B, Lajnef M, Henry C, Aubin V, Azorin JM, Bellivier F, Bougerol T, Courtet P, Gard S, Kahn JP, Passerieux C, Leboyer M; FACE-BD Clinical Coordinating Center (FondaMental Foundation); FACE-BD Data Coordinating Center (FondaMental Foundation); FACE-BD Clinical Sites and Principal Collaborators in France. Childhood trauma, dimensions of psychopathology and the clinical expression of bipolar disorders: A pathway analysis. *J Psychiatr Res* 2017;**95**:37-45.

38. Agnew-Blais J, Danese A. Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: a systematic review and meta-analysis. *Lancet Psychiatry* 2016;**3**(4):342-349.

39. Jansen K, Cardoso TA, Fries GR, Branco JC, Silva RA, Kauer-Sant'Anna M, Kapczinski F, Magalhaes PV. Childhood trauma, family history, and their association with mood disorders in early adulthood. *Acta Psychiatr Scand* 2016;**134**:281-286.

40. Hadland SE, Marshall BD, Kerr T, Qi J, Montaner JS, Wood E. Suicide and history of childhood trauma among street youth. *J Affect Disord* 2012;**136**:377-380.

41. Roy A, Janal M. Family history of suicide, female sex, and childhood trauma: separate or interacting risk factors for attempts at suicide? *Acta Psychiatr Scand* 2005;**112**:367-371.

42. Alvarez MJ, Roura P, Osés A, Foguet Q, Sola J, Arrufat FX. Prevalence and clinical impact of childhood trauma in patients with severe mental disorders. *J Nerv Ment Dis* 2011;199:156-161.
43. Aas M, Henry C, Bellivier F, Lajnef M, Gard S, Kahn JP, Lagerberg TV, Aminoff SR, Bjella T, Leboyer M, Andreassen OA, Melle I, Etain B. Affective lability mediates the association between childhood trauma and suicide attempts, mixed episodes and co-morbid anxiety disorders in bipolar disorders. *Psychol Med* 2017;47(5):902-912.
44. Janiri D, Sani G, Danese E, Simonetti A, Ambrosi E, Angeletti G, Erbuto D, Caltagirone C, Girardi P, Spalletta G. Childhood traumatic experiences of patients with bipolar disorder type I and type II. *J Affect Disord* 2015;175:92-97.
45. Krug EG, Dahlberg LL, Mercy J, Zwi A, Lozano R. Child abuse and neglect by parents and other caregivers. World Health Organization. *World Report on Violence and Health*, 2022; pp. 59-86.
46. Schoedl AF, Costa MC, Mari JJ, Mello MF, Tyrka AR, Carpenter LL, Price LH. The clinical correlates of reported childhood sexual abuse: an association between age at trauma onset and severity of depression and PTSD in adults. *J Child Sex Abus* 2010;19:156-170.

47. Ventegodt S, Flensburg-Madsen T, Andersen NJ, Merrick J. Which factors determine our quality of life, health and ability? Results from a Danish population sample and the Copenhagen perinatal cohort. *J Coll Physicians Surg Pak* 2008;18(7):445-450.
48. Erten E, Funda Uney A, Saatçioğlu Ö, Özdemir A, Fıstıkçı N, Çakmak D. Effects of childhood trauma and clinical features on determining quality of life in patients with bipolar I disorder. *J Affect Disord* 2014;162:107-113.
49. Afifi TO, Enns MW, Cox BJ, de Graaf R, ten Have M, Sareen J. Child abuse and health-related quality of life in adulthood. *J Nerv Ment Dis* 2007;195:797-804.
50. Chahine EF. Child Abuse and its Relation to Quality of Life of Male and Female Children. *Procedia-Social and Behavioral Sciences* 2014;159:161-168.
51. Maes M, Mihaylova I, Kubera M, Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2012;36(1):169-175.
52. Sowa-Kućma M, Styczeń K, Siwek M, Misztak P, Nowak RJ, Dudek D, Rybakowski JK, Nowak G, Maes M. Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of

illness, episode number, suicidal ideation and prior suicide attempts. *Prog Neuropsychopharmacol Biol Psychiatry* 2018;81:372-383.

53. Celik C, Erdem M, Cayci T, Ozdemir B, Ozgur Akgul E, Kurt YG, Yaman H, Isintas M, Ozgen F, Ozsahin A. The association between serum levels of neopterin and number of depressive episodes of major depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010;34(2):372-5. doi: 10.1016/j.pnpbp.2010.01.002. Epub 2010 Jan 13. PMID: 20074610.

54. de Melo LGP, Nunes SOV, Anderson G, Vargas HO, Barbosa DS, Galecki P, Carvalho AF, Maes M. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2017;78:34-50.

55. Nunes CS, Maes M, Roomruangwong C, Moraes JB, Bonifacio KL, Vargas HO, Barbosa DS, Anderson G, de Melo LGP, Drozdziej S, Moreira E, Carvalho AF, Nunes SOV. Lowered quality of life in mood disorders is associated with increased neuro-oxidative stress and basal thyroid-stimulating hormone levels and use of anticonvulsant mood stabilizers. *J Eval Clin Pract* 2018;24(4):869-878.

56. Maes M, Vasupanrajit A, Jirakran K, Klomkliew P, Chanchaem P, Tunvirachaisakul C, Plaimas K, Suratane A, Payungporn S. Adverse childhood experiences and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviours and the phenome of major

depression: towards enterotypic phenotypes. *Acta Neuropsychiatr.* 2023;35(6):328-345. doi: 10.1017/neu.2023.21. Epub 2023 Apr 13. PMID: 37052305.

57. Maes M, Rachayon M, Jirakran K, Sodsai P, Sughondhabirom A. Lower Nerve Growth Factor Levels in Major Depression and Suicidal Behaviors: Effects of Adverse Childhood Experiences and Recurrence of Illness. *Brain Sci.* 2023;13(7):1090. doi: 10.3390/brainsci13071090. PMID: 37509019; PMCID: PMC10377511.

58. Maes M, Rachayon M, Jirakran K, Sughondhabirom A, Sodsai P. Effects of recurrence of illness and adverse childhood experiences on effector, cytotoxic, and regulatory T cells, and cannabinoid receptor-bearing B cells in major depression, an autoimmune disorder. medRxiv 2023.06.11.23291243; doi: <https://doi.org/10.1101/2023.06.11.23291243>

59. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Mol Psychiatry* 2013;18(5):595-606.

60. Maes M, Barbosa DS, Almulla AF, Kanchanatawan B. A Novel Pathway Phenotype of Temporal Lobe Epilepsy and Comorbid Psychiatric Disorders: Results of Precision Nomothetic Medicine. *Antioxidants (Basel).* 2022;11(5):803. doi: 10.3390/antiox11050803. PMID: 35624666; PMCID: PMC9137678.

61. Aryutova K, Paunova R, Kandilarova S, Stoyanova K, Maes MH, Stoyanov D. Differential aberrant connectivity of precuneus and anterior insula may underpin the diagnosis of schizophrenia and mood disorders. *World J Psychiatry*. 2021;11(12):1274-1287. doi: 10.5498/wjp.v11.i12.1274. PMID: 35070777; PMCID: PMC8717032.
  
62. Stojanov D, Korf J, Jonge P, Popov G. The possibility of evidence-based psychiatry: depression as a case. *Clinical Epigenetics* 2011;2(1):7.
  
63. Al-Hakeim HK, Al-Naqeeb TH, Almulla AF, Maes M. The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium. *J Affect Disord*. 2023;331:300-312. doi: 10.1016/j.jad.2023.03.072. Epub 2023 Mar 28. PMID: 36996718.

## Figures

**Figure 1** Partial regression of the recurrence of illness (ROI) index on the sum of three selected adverse childhood experience (ACE) domains ( $p < 0.01$ )

**Figure 2** Partial regression of the METAMMUNE index on recurrence of illness (ROI) scores ( $p < 0.01$ ).

**Figure 3** Partial regression of the INT (immune-linked neurotoxicity) index on recurrence of illness (ROI) scores ( $p < 0.01$ ).

**Figure 4** Partial regression of the lifetime phenome score on the recurrence of illness (ROI) index ( $p < 0.01$ )

**Figure 5** Partial regression of the current phenome on the recurrence of illness (ROI) index ( $p < 0.01$ )



**Table 1.** Demographic and clinical data of outpatients with major depressive disorder (OMDD) and healthy controls (HC)

<b>Variables</b>	<b>HC (n=67)</b>	<b>OMDD (n=66)</b>	<b>F/<math>\chi^2</math>/FET</b>	<b>df</b>	<b>p</b>
Age (years)	37.9 (9.2)	37.0 (11.5)	0.26	1/131	0.609
Sex (Female/Male)	58/9	48/18	3.94	1	0.055
Education (years)	14.1 (3.4)	14.8 (2.8)	1.72	1/131	0.193
S/M/W/D	35/26/3/3	36/22/4/4	0.739	-	0.877
Employed/unemployed	65/2	51/15	11.62	1	0.001
Current smoking (yes/no)	63/4	57/9	2.22	1	0.156
Body mass index (kg/m <sup>2</sup> )	27.39 (6.11)	26.87 (5.49)	0.27	1/130	0.607
Metabolic syndrome (No/Yes)	34/33	35/31	0.07	1	0.863
Lifetime Covid-19 history (yes/no)	62/5	62/4	FET	-	1
Total ACE score	18.4 (8.6)	26.5 (9.1)	27.23	1/131	<0.001
3ACE score	9.9 (1.5)	15.8 (6.1)	34.44	1/131	<0.001
Self-rated number of episodes	0	3.9 (4.0)	MWU	-	<0.001
OPD-rated number of episodes	0	2.8 (1.8)	MWU	-	<0.001
Lifetime suicidal ideation	0.0	0.90 (1.54)	MWU	-	<0.001
Lifetime suicide attempts	0.0	0.81 (0.36)	MWU	-	<0.001
ROI (z score)	-0.702 (0)	0.713 (1.002)	MWU	-	<0.001
ROI adjusted (z score)	-0.669 (0)	0.679 (1.049)	MWU	-	<0.001
Any lifetime anxiety disorder (No/Yes)	67/0	48/18	FET	-	<0.001
Lifetime dysthymia (No/Yes)	67/0	42/24	FET	-	<0.001
Neuroticism score	18.3 (5.0)	27.2 (6.4)	80.33	1/131	<0.001
Lifetime phenome (z score)	-0.594 (0.298)	0.603 (1.092)	74.92	1/131	<0.001
Beck Depression Inventory	5.6 (6.5)	26.9 (13.8)	129.52	1/131	<0.001
Hamilton Depression Rating Scale	2.3 (3.0)	18.1 (6.4)	330.94	1/131	<0.001
STAI	38.2 (7.8)	51.9 (10.4)	73.62	1/131	<0.001
Current phenome (z score)	-0.759 (0.421)	0.770 (0.809)	187.44	1/131	<0.001

Immune network index (z score)	-0.304 (0.937)	0.308 (0.973)	13.65	1/131	0.001
INT index (z score)	-0.488 (0.744)	0.496 (0.978)	42.71	1/131	<0.001
MEATAMMUNE (z score)	-0.494 (0.894)	0.457 (0.885)	34.54	1/131	<0.001

Results are shown as mean (S.D.); F: results of analysis of variance;  $\chi^2$ : analysis of contingency tables; FET: Fisher-exact probability test; S/M/W/D: single/married/widowed/divorced; ACE: adverse childhood experiences; ROI: recurrence of illness index; INT: immune-linked neurotoxicity.

**Table 2.** Results of principal component analysis.

<b>ROI</b>		<b>ROI pathway phenotype</b>	
<b>Variables</b>	<b>Loading</b>	<b>Variables</b>	<b>Loading</b>
Number of episodes	0.801	Number of episodes	0.778
Lifetime suicidal ideation	0.934	Lifetime suicidal ideation	0.832
Lifetime suicidal attempts	0.858	Lifetime suicidal attempts	0.734
		INT index	0.716
		METAMMUNE index	0.737
KMO = 0.622		KMO = 0.663	
$X^2 = 181.793$ (df=3), $p < 0.001$		$X^2 = 331.921$ (df=10), $p < 0.001$	
VE = 75.02%		VE = 57.82%	
Cronbach's alpha=0.819		Cronbach's alpha=0.810	

KMO: The Kaiser-Meyer-Olkin Test; VE: Variance explained;  $X^2$ : Bartlett's test of sphericity.  
 INT: immune-linked neurotoxicity index

**Table 3.** Results of multiple regression analyses with recurrence of illness (ROI) data as dependent variables and adverse childhood experiences and biomarkers as explanatory variables.

Dependent Variables	Explanatory Variables	Coefficients of input variables			Model statistics			
		$\beta$	t	p	R <sup>2</sup>	F	df	p
#1. Number of episodes	<b>Model</b>				0.191	31.02	1/131	<0.001
	Total ACE score	0.438	5.57	<0.001				
#2 ROI	<b>Model</b>				0.227	19.13	2/130	<0.001
	Total ACE score	0.451	5.85	<0.001				
	Male sex	0.170	2.20	0.030				
#3. ROI	<b>Model</b>				0.202	10.88	3/129	<0.001
	Divorce	0.241	2.91	0.004				
	Physical abuse	0.279	3.54	0.001				
	Sexual abuse	0.172	2.09	0.039				
#4. ROI	<b>Model</b>				0.305	14.06	4/128	<0.001
	Emotional abuse	0.207	2.46	0.015				
	METAMMUNE index	0.255	3.28	0.001				
	Divorce	0.203	2.67	0.009				
	Emotional neglect	0.169	1.99	0.049				

ACE: adverse childhood experiences

**Table 4.** Correlation matrix between recurrence of illness (ROI) index and clinical and biomarker data.


<b>Variables</b>	<b>ROI in all subjects N=133</b>	<b>ROI in MDD only N=66</b>
3ACE score	0.503 **	0.254 *
Total ACE score	0.509 **	0.274 *
Neuroticism score	0.640 **	0.312 *
Lifetime phenome	0.714 **	0.414 *
Hamiton Depression Rating Scale score	0.823 **	0.209
Beck Depression Inventory score	0.732 **	0.318 *
State Train Anxiety Inventory, state score	0.603 **	0.206
Current suicidal behaviours	0.689 **	0.486 **
Current phenome	0.764 **	0.312 *
Immune network index	0.328 **	0.094
Immune-linked neurotoxicity index	0.461 **	0.049
METAMMUNE INDEX	0.336 **	0.256 *

Results of Spearman's rank-order correlation calculations; \*\*p<0.01; \* p<0.05.


**Table 5.** Results of multiple regression analyses with clinical scores as dependent variables and biomarkers and adverse childhood experiences as explanatory variables.

Dependent Variables	Explanatory Variables	Coefficients of input variables			Model statistics			
		$\beta$	t	p	R <sup>2</sup>	F	df	p
#1. LT_phenome	<b>Model</b>				0.474	58.49	2/130	<0.001
	ROI	0.549	7.94	<0.001				
	Emotional abuse	0.253	3.67	<0.001				
#2. Current_phenome	<b>Model</b>				0.551	39.29	4/128	<0.001
	ROI	0.444	6.42	<0.001				
	Emotional neglect	0.188	2.72	0.007				
	INT	0.209	3.26	0.001				
	Emotional abuse	0.164	2.38	0.019				
#3. Current_phenome in MDD	<b>Model</b>				0.409	10.57	4/61	<0.001
	Age	-0.398	-3.98	<0.001				
	Emotional neglect	0.355	3.50	0.001				
	Sexual abuse	0.228	2.24	0.029				
	ROI x MetS	0.221	2.23	0.029				

ROI: recurrence of illness index; INT: immune-linked neurotoxicity; MetS: metabolic syndrome




**Figure 1** Partial regression of the recurrence of illness (ROI) index on the sum of three selected adverse childhood experience (ACE) domains ( $p < 0.01$ )




**Figure 2** Partial regression of the METAMMUNE index on recurrence of illness (ROI) scores ( $p < 0.01$ ).






**Figure 3** Partial regression of the INT (immune-linked neurotoxicity) index on recurrence of illness (ROI) scores ( $p < 0.01$ ).



**Figure 4** Partial regression of the lifetime phenome score on the recurrence of illness (ROI) index ( $p < 0.01$ )



**Figure 5** Partial regression of the current phenome on the recurrence of illness (ROI) index ( $p < 0.01$ )